Month: February 2019

Our Acquisition of Trehalose and Collaboration with Team Sanfilippo Foundation (TFS)

Our Acquisition of Trehalose and Collaboration with Team Sanfilippo Foundation (TFS) by Anthony Marciano On February 19, 2019, Seelos Therapeutics, Inc. (Nasdaq: SEEL) announced a definitive agreement with Bioblast Pharma Ltd., (Nasdaq: ORPN), whereby Seelos acquired all development and commercial rights to Bioblast’s proprietary trehalose 90 mg/mL IV (Trehalose) solution as well as the existing…
Read more

Addressing Suicidality

Addressing Suicidality by Samantha Miernicki, PharmD Every 12 minutes, approximately one death occurs due to suicide, according to the most recent data published in 2016 from the Centers of Disease Control and Prevention. In 2016, 9.8 million American adults seriously thought about suicide, 2.8 million created a plan to commit suicide, and 1.3 million attempted…
Read more